Phase 3 Carcinoma, Non-Small Cell Lung Clinical Trials
12 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–12 of 12 trials
Recruiting
Phase 3
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled361 locationsNCT06890598
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled353 locationsNCT06875310
Recruiting
Phase 3
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Carcinoma, Non-Small Cell LungResectable Lung Non-Small Cell CarcinomaLung Diseases
Fundación GECP129 enrolled32 locationsNCT06431633
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
AstraZeneca830 enrolled296 locationsNCT06868277
Recruiting
Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC680 enrolled232 locationsNCT06623422
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer714 enrolled329 locationsNCT06758401
Recruiting
Phase 3
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Carcinoma, Non-Small Cell Lung
Maia Biotechnology300 enrolled15 locationsNCT06908304
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaCarcinoma, Non-Small Cell LungOvarian Neoplasms+9 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 3
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Carcinoma, Non-Small Cell Lung
AstraZeneca280 enrolled105 locationsNCT06008093
Recruiting
Phase 3
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Carcinoma, Non-Small Cell Lung
Qilu Pharmaceutical Co., Ltd.632 enrolled1 locationNCT05487391